StartseiteMCPWorkbenchSkills
StartseiteWorkbenchBenachrichtigungenMein Bereich
llms.txt · MCP-AnleitungDatenschutz · Nutzungsbedingungen · Supportv1.8.3
  1. Startseite
  2. /Reaktion

Triethylamine → HCID 178455614, Verbindung

HRID 274772
Drucken

Reaktionsgleichung

Reaktionsgleichung von HRID 274772
[NH2:1][CH:2]([CH2:13][CH:14]1[CH2:19][CH2:18][CH2:17][CH2:16][CH2:15]1)[CH:3]([OH:12])[CH:4]([C:6]1[CH2:11][CH2:10][CH2:9][CH2:8][CH:7]=1)[OH:5].[C:20]([S:24]([CH2:27][C@@H:28]([CH2:54][C:55]1[CH:60]=[CH:59][CH:58]=[CH:57][CH:56]=1)[C:29]([NH:31][C@H:32]([C:51](O)=[O:52])[CH2:33][C:34]1[N:38](C2C=CC([N+]([O-])=O)=CC=2[N+]([O-])=O)[CH:37]=[N:36][CH:35]=1)=[O:30])(=[O:26])=[O:25])([CH3:23])([CH3:22])[CH3:21].C(N(CC)CC)C.C1C=CC2N(O)N=NC=2C=1.CN(C(ON1N=NC2C=CC=CC1=2)=[N+](C)C)C.F[P-](F)(F)(F)(F)F.[N+](C1C=C([N+]([O-])=O)C=CC=1N1C=C(CCC(N)=O)N=C1)([O-])=O.C(O)(=S)C(C)O>C(#N)C.CN(C)C=O>[C:20]([S:24]([CH2:27][C@@H:28]([CH2:54][C:55]1[CH:56]=[CH:57][CH:58]=[CH:59][CH:60]=1)[C:29]([NH:31][C@@H:32]([CH2:33][C:34]1[N:38]=[CH:37][NH:36][CH:35]=1)[C:51]([NH:1][C@@H:2]([CH2:13][CH:14]1[CH2:19][CH2:18][CH2:17][CH2:16][CH2:15]1)[C@@H:3]([OH:12])[C@H:4]([C:6]1[CH2:11][CH2:10][CH2:9][CH2:8][CH:7]=1)[OH:5])=[O:52])=[O:30])(=[O:26])=[O:25])([CH3:23])([CH3:21])[CH3:22]
KomponentenVersuchsvorschriftAufarbeitungQuellen und NachweiseNotizen zur Reaktion

Komponenten

10

Edukt 7

HCID 8471TriethylamineHCID 757711-HydroxybenzotriazoleHCID 2733084Methanaminium, N-((1H-benzotriazol-1-yloxy)(dimethylamino)methylene)-N-methyl-, hexafluorophosphate(1-) (1:1)HCID 22845096N-[(S)-alpha-[(t-butylsulphonyl)methyl]hydrocinnamoyl]-3-(2,4-dinitrophenyl)-L-histidineHCID 545040113-Amino-4-cyclohexyl-1-(1-cyclohexen-1-yl)-1,2-butanediol
HCID 131717471
1-(2,4-Dinitrophenyl)imidazol-4-propionamide
HCID 178473673HCID 178473673, Verbindung

Produkt 1

HCID 178455614HCID 178455614, Verbindung

Reagenzien, Katalysatoren, Lösungsmittel 2

HCID 6228DimethylformamideLösungsmittelHCID 6342AcetonitrileLösungsmittel

Versuchsvorschrift

A mixture of 100 mg (0.37 mmol) of (1S or R,2R,3S)-3-amino-4-cyclohexyl-1-(1-cyclohexen-1-yl)-1,2-butanediol and 257 mg (0.41 mmol) of N-[(S)-α-[(t-butylsulphonyl)methyl]hydrocinnamoyl]-3-(2,4-dinitrophenyl)-L-histidine in 15 ml of acetonitrile is treated under argon in succession at room temperature with 83 mg (0.82 mmol) of triethylamine, 67 mg (0.41 mmol) of HOBT and 168 mg (0.41 mmol) of HBTU and the reaction mixture is thereafter stirred at room temperature for 3 hours. For the working-up, the reaction mixture is concentrated under reduced pressure to about 1/4 of the original volume, then diluted with 50 ml of ethyl acetate and washed in succession with water, saturated sodium bicarbonate solution, water and saturated sodium chloride solution. The organic phase is dried over sodium sulphate and evaporated under reduced pressure, and the residue is chromatographed on silica gel with a 98:2 mixture of methylene chloride and methanol as the eluting agent, whereby there are obtained 140 mg (0.17 mmol) of (S)-α-[(S)-α-[(t-butylsulphonyl)methyl]hydrocinnamido]-N-[(1S,2R,3S or R)-1-(cyclohexylmethyl)-3-(1-cyclohexen-1-yl)-2,3-dihydroxypropyl]-1-(2,4-dinitrophenyl)imidazol-4-propionamide in the form of a yellow foam, MS: 838 (M+H)+. This is dissolved in 3 ml of dimethylformamide and stirred at room temperature for 3 hours with 0.15 ml (1.7 mmol) of thiolactic acid. Thereafter, the reaction solution is evaporated in a high vacuum, the residue is dissolved in 15 ml of ethyl acetate and the reaction solution is washed in succession with saturated sodium carbonate solution, water and saturated sodium chloride solution. The yellowish coloured ethyl acetate phase is dried over sodium sulphate and evaporated under reduced pressure. For purification, the residue (120 mg) is chromatographed on silica gel with a 95:5 mixture of methylene chloride and methanol, which contains 0.1% ammonium hydroxide, as the eluting agent. After lyophilization from dioxan there are obtained 85 mg of (S)-α-[(S)-α-[(t-butylsulphonyl)methyl]hydrocinnamamido]-N-[(1S,2R,3S)-3-(1-cyclohexen-1-yl)-1-(cyclohexylmethyl)-2,3-dihydroxypropyl]Imidazole-4-propionamide as a yellowish powder, MS: 671 (M+H)+.

Aufarbeitung

  1. concentrationthe reaction mixture is concentrated under reduced pressure to about 1/4 of the original volume
  2. additiondiluted with 50 ml of ethyl acetate
  3. washwashed in succession with water, saturated sodium bicarbonate solution, water and saturated sodium chloride solution
  4. dry with materialThe organic phase is dried over sodium sulphate
  5. customevaporated under reduced pressure
  6. customthe residue is chromatographed on silica gel with a 98:2 mixture of methylene chloride and methanol as the eluting agent, whereby there
  7. customare obtained 140 mg (0.17 mmol) of (S)-α-[(S)-α-[(t-butylsulphonyl)methyl]hydrocinnamido]-
  8. customThereafter, the reaction solution is evaporated in a high vacuum
  9. dissolutionthe residue is dissolved in 15 ml of ethyl acetate
  10. washthe reaction solution is washed in succession with saturated sodium carbonate solution, water and saturated sodium chloride solution
  11. dry with materialThe yellowish coloured ethyl acetate phase is dried over sodium sulphate
  12. customevaporated under reduced pressure
  13. customFor purification
  14. customthe residue (120 mg) is chromatographed on silica gel with a 95:5 mixture of methylene chloride and methanol, which

Quellen und Nachweise

ORD-Eintrag
ord-4e6053cb62bb472db61c1e876381af70
Quelldatensatz
uspto-grants-1995_02
DOI
10.6084/m9.figshare.5104873.v1
Patentnummer
US05389616

Notizen zur Reaktion

Auf dieser SeiteKomponentenVersuchsvorschriftAufarbeitungQuellen und NachweiseNotizen zur Reaktion